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Vol XXVII Issue No. 2 Spring 2010 
Special Antimicrobial Resistance Issue 
Bad Bugs Including No ESKAPE—Antimicrobial Resistance in Hospitals and 

Communities Continues to Challenge 

ABSTRACT 
The global burden of antibiotic resistance in 2010 occurs 
with limited future antimicrobial choices and with a need for 
the practitioner to make the most effective use of those 
antibiotics that are currently available to preserve their
usefulness.  Antibiotic selection for individual patients now 
impacts both inpatient and outpatient resistance, the
carriage of more resistant and/or virulent bacteria, and 
more aggressive bacteria resulting in disease with increased 
complications, morbidity, and mortality.
This article addresses updated evidence, with an 
epidemiologic and clinical focus, pertaining to the new 
resistance and/or virulence challenges with Streptococcus
pneumoniae, Clostridium difficile, and community-
associated methicillin-resistant Staphylococcus aureus 
(MRSA).  A pragmatic and clinical introduction to 
heteroresistant vancomycin-intermediate Staphylococcal
aureus (hVISA) is accomplished and an important 
pharmacologic update on new vancomycin therapeutic 
guidelines is presented, with the clinical goal improved 
MRSA morbidity and mortality.
This special issue 
supplements 
earlier Epi Notes
and DHEC 
website updates 
that address SN 
and CA-MRSA 
resistance 
challenges and 
outpatient clinical 
management. 
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Increased risk of antibiotic resistance continues to 
impact significantly our practices, while experts warn 
that antibiotic misuse and declining development of 
new medicines may render current antibiotics 
increasingly ineffective. Our patients and families are 
aware of some of our challenges [see “A Deadly Bug
Invades Our Towns,” in the December 7, 2008 Parade 
Magazine and “Battling Superbugs,” the March 2009 
AARP Bulletin series of articles addressing the methicillin-
resistant Staphylococcus aureus (MRSA) epidemic and 
the rising threat of Clostridium difficile]. It is in primary
care practices that efforts to sustain the lifespan of 
current antibiotics must originate. 
The Infectious Diseases Society of America (IDSA) 
continues to view with concern the lean pipeline for novel 
therapeutics to treat drug-resistant infections.  The IDSA’s 
“Bad Bugs, No Drugs” initiative is focused on multidrug-
resistant pathogens in the hospital and in the community 
coined the acronym ESKAPE bacteria – Enterococcus
faecium, Staphylococcus aureus, Klebsiella sp., 
Acinetobacter baumanii, Pseudomonas aeruginosa, and 
Enterobacter sp. representing two-thirds of all healthcare-
associated infections.1  The following discussion relates 
the pragmatism of antimicrobial resistance to the 
practitioner’s inpatient and outpatient challenges with a
contemporary epidemiologic and clinical perspective of 
Streptococcus pneumoniae (SN), Clostridium difficile
(CD), and community-associated methicillin-resistant 
Staphylococcal aureus (CA-MRSA).
It is in primary care practices that 
efforts to sustain the lifespan of
current antibiotics must originate. (Continued on page 4)
www.scdhec.gov/health/disease/
  
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
  
Page 2 Spring 2010 Epi Notes
Over-Prescribing of Antibiotics: Truly Not a Benign Practice 
P. Brandon Bookstaver, PharmD, Clinical Assistant Professor, Clinical Pharmacy and Outcomes 

Sciences, South Carolina School of Pharmacy, Columbia Campus 

John A. Bosso, PharmD, FCCP, FIDSA, Professor, Chair, Clinical Pharmacy and Outcomes Sciences, 

South Carolina School of Pharmacy, Charleston Campus 

Patients with acute respiratory infections in the 
community seeking antibiotics typically emerge from an 
ambulatory care clinic or office rewarded for their visit with 
an antibiotic prescription in hand.  Antibiotics are 
prescribed during nearly 1/5 of all outpatient physician
visits annually.1  Despite efforts to curb antibiotic
prescribing, unnecessary antibiotic usage continues to be 
a widespread practice, as nearly 67% of adults with acute 
bronchitis received antibiotic therapy in 2005.2  In 
considering acute respiratory tract infections in general, it 
has been estimated that 55% of antibiotic prescriptions 
are unnecessary.3 Long-term effects of the over-
prescribing of antibiotics such as the influence on local 
susceptibility rates and inherent pressures on emerging 
resistance patterns are well documented and usually 
stressed in outreach programs and professional 
communication meant to discourage unnecessary 
antibiotic use.  Unfortunately, little attention has been paid 
to the negative short-term untoward effects of antibiotics, 
notably the adverse drug effects (ADE), including 
allergic reactions.  Overall, ADEs account for up to 2.8% 
of hospital admissions and are recognized as a leading 
cause of mortality in the United States.4,5  ADEs
secondary to antibiotics contribute greatly to these 
numbers and ultimately lead to an increase in office and 
emergency room visits, hospitalizations, healthcare costs 
and the potential for significant morbidity and mortality. 
Stereotypically, antibiotics have been labeled by clinicians
as a benign therapy with a consistently favorable risk:
benefit profile.  Emerging data does not support this 
notion, and in fact refutes it altogether.  In an article 
published in June 2008, Shehab and colleagues describe 
an investigation of the rate and impact of ADEs 
secondary to antibiotics.6  The authors reported that 
nearly 150,000 Emergency Department (ED) visits 
annually were due to adverse events associated with 
antibiotics. Approximately 80% of these adverse events 
were attributed to allergic reactions with beta-lactams,
identified as the primary offenders.6  Allergic-type 
reactions were typically mild in nature, however, 
significant life-threatening IgE-mediated anaphylactic
reactions may occur in up to 1 in 5,000 to 10,000 patients 
posing a significant mortality risk.7,8  Given the 
considerable availability of antibiotic samples and 
frequent “pharmacy shopping” among patients, allergy 
reporting is increasingly important, yet more cumbersome 
and less accurate, posing an even greater threat to the
public.   
Shehab and colleagues reported the number of ED visits 
to be highest in patients aged 15-44, comprising over
40% of all visits.6  Pediatric patients (< 15 years) 
accounted for nearly 25% of all ED visits secondary to 
ADEs from antibiotics, with infants less than 1 year 
accounting for the highest overall ED visit rate of 15.9 ED 
visits per 10,000 outpatient prescription visits.  Nearly 
15% of visits were observed in the elderly population (> 
65 years of age).6  These rates of ADEs are concerning
as, in these particularly vulnerable populations, significant 
morbidity may result from moderate-to-severe ADEs.
Approximately 1% of all ED visits resulted in 
hospitalization.6  The average cost of an admission
secondary to an ADE is estimated to be $4000 - $6000
per admission – which should be considered avoidable 
costs.4 
Which adverse drug effects are most common? 
Gastrointestinal complaints or symptoms are a common 
ADE associated with antibiotic therapy.  Up to 25% of 
patients will develop antibiotic-associated diarrhea 
(AAD).8  Although causing personal discomfort and 
anxiety, AAD is generally considered a mild side-effect 
carrying very low rates of morbidity and mortality.  
However, of significant concern is the development of 
Clostridium difficile- infection/diarrhea (CDI).  Many 
believe use of antibiotics is the single greatest risk factor 
for developing CDI.9  Although primarily a nosocomially-
acquired pathogen, reports of community-acquired 
infections continue to accumulate.  Clindamycin, 3rd 
generation cephalosporins and fluoroquinolones have
been associated with the highest risk – but all antibiotics 
capable of altering the normal gastrointestinal flora should 
be considered associated risk factors for CDI.9  CDIs can 
be associated with significant morbidity and sequelae, 
including prolonged hospitalization with attendant 
increased cost and the potential for death in high-risk 
patients. 
Thus, the prescribing of antibiotics should not be 
considered a benign practice with little downside or 
negative short-term impact.  Immediate ADEs secondary 
to antibiotics are real, significant and largely avoidable 
given the recognized shift in risk: benefit ratio for the 
patient. Both potential ADEs and startlingly rising rates of 
bacterial resistance should give the care provider pause 
before prescribing antibiotics in dealing with a case with a 
less than convincing causative bacterial infection.
(Continued on page 14)
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A Message from DHEC’s Bureau of Disease Control 
James “Jerry” Gibson, MD, MPH, State Epidemiologist, Director, SC DHEC Bureau of Disease Control
The increasing problem of antimicrobial resistance in healthcare associated and community associated 
infections continues to challenge the practicing clinician and affect the public’s health. Recognizing this
serious public health problem has resulted in this unique edition of the DHEC Epi Notes focusing entirely
on antibiotic resistance and the individual clinician’s decision making with each patient. Decisions on
antimicrobials will now determine who in our community carries or is infected with the new, more 
virulent Strep pneumoniae isolates, the more virulent CA-MRSA isolates, or who experiences GI
infection with the new hyper-virulent C. difficile isolates.
We hope the updated information in this Epi Notes issue will promote the most appropriate 
utilization of antimicrobials in your daily practice. 
SC Careful Antibiotic Use (SC CAUse): Resources for the Practicing Clinician 
Dixie F. Roberts, APRN, MPH, Director, Healthcare Infections and Antibiotic Resistance Section, 

SCDHEC Bureau of Disease Control 

Antibiotics are essential and can be life-saving.  However, antibiotic resistance is a major public health problem.  Careful 
antibiotic use of antibiotics (stewardship) is critical to maintain their availability and to minimize any risks to individual 
patients. According to Centers for Disease Control and Prevention (CDC), more than ten million courses of antibiotics are 
prescribed each year for viral conditions, which do not benefit from antibiotics.  It is recognized that these prescribing 
trends reflect the national downward trend over time; however, it is important that the antibiotic prescribing rates continue
to decline.  There is significant and growing evidence that a 
single prescription to an individual patient in the community or a 
broad spectrum antibiotic to a hospitalized patient now 
significantly affects each patient and the community. 
DHEC collaborated with Pharmacy Professor, Dr. Mike Dickson, 
from the SC College of Pharmacy, Columbia to ascertain trends 
in antibiotic prescribing practices from SC Medicaid claims data 
for visits for common upper respiratory infections (URIs).  Each
visit was matched with the drug and the dose of the prescriptions 
filled. Evidence suggests that educational efforts by professional 
associations, public health, and other community efforts have 
been effective in decreasing over prescribing of antibiotics for 
viral URIs in South Carolina since 1998 (as shown in the lower, 
solid line on the graphic.)  These data are available from the SC 
CAUse website. 
The SC CAUse program has prepared resources for practicing 
clinicians in the community and in healthcare facilities to use in educating their patients about when antibiotics are not
needed and to promote the judicious use of antibiotics in healthcare facilities (stewardship).  SC Careful Antibiotic Use 
(CAUse) and Antimicrobial Stewardship information is available on the following websites:  
♦ SC CAUse: www.scdhec.gov/sccause
♦ CDC Antimicrobial Resistance in healthcare facilities  www.cdc.gov/ncidod/dhqp/ar.html
♦ CDC Get Smart About Antibiotics Campaign www.cdc.gov/getsmart/index.html
Get Smart About Antibiotics: 
Because Sometimes the Best Medicine is No Medicine 
DHEC SC CAUse is a partner with the CDC’s Get Smart About Antibiotics Campaign and will be participating in the 
campaign for provider and community education throughout the year.  This year, Get Smart About Antibiotics Week will 
coincide with Europe’s community careful use education campaign to emphasize the global impact of antibiotic resistance.  
SC CAUse will be participating in Get Smart Week activities.  We will be providing more information through our website.  
Get Smart About Antibiotics Week - November 15 – 21, 2010
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Bad Bugs, Including No ESKAPE 
(Continued from page 1) and transmission of 
The public and legislatures are becoming significantly
aware of “superbugs,” appropriate antibiotic use, and 
hand-washing in the hospital setting (healthcare workers 
clean their hands effectively only about half the time).  On 
October 1, 2008, Medicare stopped paying for 
complications arising from certain infections and 
conditions that result 
from hospital care and Currently, there are no new
are “reasonably classes of antibiotic 
preventable.”  
entering late-stage clinical
The S.C. State development.  Since 2000, Legislature in May 2006 
passed the Hospital two new classes of 
Infection Disclosure antibiotics have been 
Act2 designed to assure approved for use with none that the public has 
access to information 1970-2000 compared with 
on hospital acquired 10, 1930-1960.  
infections in each 
hospital along with 
recent legislation addressing resistance patterns within 
our state.  This is noteworthy in that all antimicrobial 
resistance problems come down to antimicrobial
selective pressure and infection control.3 
Efforts to sustain the lifespan of current antibiotics are 
vital. Several major medical associations warn that 
antibiotic resistance is the number one problem facing the 
medical community.  With most practices currently 
managing community infections successfully, experts 
worry providers will not have effective antibiotics to treat 
all patients in the future.  One way to overcome antibiotic 
resistance would be to get more specific with treatment; 
for example, rapid Streptococcus pyogenes testing for 
sore throat /pharyngitis can reduce unnecessary antibiotic 
prescriptions by more than 50%.  Another way for 
providers to address antibiotic resistance is to become 
educated about which drugs create the most antibiotic 
pressure, remembering that some are worse than others 
at driving resistance.  This is especially the case when 
physicians use antibiotics at times much beyond what is 
needed (e.g., amoxicillin and amoxicillin clavulanate have 
much less of an effect on antibiotic pressure than 
macrolides and cephalosporins).  Antibiotic usage at both 
patient and hospital levels correlates with the risk of 
multidrug-resistant bacteria, i.e., antimicrobial exposure 
increases the risk of MRSA acquisition 2-3 fold depending 
on drug class.4 
Pneumococcus Epidemiology / Clinical Update 
Asymptomatic nasopharyngeal (NP) carriage of 
pneumococci is an important factor in the development 
pneumococcal disease, Clinical challengeswith carriage rates 
varying by serotype, grow with infections 
ranging from 11-75% at acquired in hospitals
any one time. Up to 
resulting in 99,00054% of children carry 
pneumococci by one patient deaths per year 
year of age.5  NP 
(hospital infections kill carriage may occur in up
to 60% of healthy more Americans each 
preschool children and year than AIDS, breastup to 30% of older 
children and adults.6 cancer, and automobile 
Widespread use of accidents combined).
pneumococcal conjugate 
vaccine (PCV7) resulted 
in decreases in invasive pneumococcal disease (IPD) 
among children and elderly persons with the incidence of 
pneumococcal disease caused by virulent clones of non-
vaccine serotypes increasing.73,74 Significantly, a more 
virulent appearing non-vaccine serotype 19A has 
become the predominant cause of invasive disease in 
children, (accounting for 44% of isolates in 8 children’s 
7,8,73hospitals).   Massachusetts data over the recent half 
decade9 have revealed non-vaccine serotypes as the 
etiology of 72-91% of invasive pneumococcal disease
annually in children less than 5 years of age.  Those 
same data demonstrate that the mortality from invasive
pneumococcal disease in children less than one year of 
age is approximately ten times higher than for those aged 
1-10 years – about 3% of whom develop invasive 
disease.  Several studies have shown that
nasopharyngeal carriage of 19A serotype has greatly 
increased (e.g., from 3.5% in 2000 to 19% in 2004) since 
the introduction of PCV7.10,11  A recent study (sampling 
data was two-thirds noninvasive respiratory sources at 80 
study sites) collected S. pneumoniae isolates from 
subjects < 14 years old with non-vaccine serotypes 
accounting for 89.1%, with serotype 19A most prevalent 
representing 30.5% of all isolates.12 
Another study with S. pneumoniae tympanocentesis
isolates revealed 40% were serotype 19A (the most 
common serotype isolated) with 23% of these resistant to 
multiple antimicrobial drugs including one otopathogen 
strain resistant to all FDA-approved antibiotics for 
treatment of acute otitis media in children.13,14  Overall, 
the most recent literature suggests approximately 60-75% 
of S. pneumoniae otopathogen isolates are penicillin 
susceptible/intermediate in sensitivity.  Recent 
epidemiology also suggests otopathogens in persistent, 
(Continued on page 5)
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Bad Bugs, Including No ESKAPE 
(Continued from page 4)
acute otitis media (AOM) and AOM treatment failure have 
changed with H. influenza (Hi) the predominant 
pathogen.15 Three events are influencing S. pneumoniae
epidemiologic trends – expansion of existing clones, 
introduction of new clones, and capsule switching.  In 
2005-2006, Pneumococcal macrolide resistance in the 
U.S. showed its first significant increase since 2000 with 
an increase from 34.1% to 39.4% with 50.4% resistance 
noted in respiratory isolates in children less than two 
years of age.16  Because non-vaccine serotype 
replacement is significant, it appears prudent to continue 
a traditional approach to the management of the febrile 
young infant and child.17 
Failure to achieve early bacterial eradication during 
antibiotic therapy for acute otitis media (AOM) increases 
clinical failure rates.  Guidelines18 for the treatment of 
AOM in children, including consideration of no treatment 
with select criteria, establish a clear hierarchy among the 
various antibacterials for treatment.  The effect of 
treatment did not differ very much from one drug to 
another when AOM is caused by a penicillin-susceptible 
pneumococcus (range of failures 0-10% for all antibiotics 
studied).  Major differences appear with non-susceptible 
pneumococci with cefdinir ineffective in eradicating most 
non-susceptible pneumococci.  Azithromycin and 
trimethoprim are similar to placebo in eradicating resistant 
pneumococci.  High doses of amoxicillin, amoxicillin/ 
clavulanate, and 3 doses of ceftriaxone show significant 
efficacy in the eradication of non-susceptible 
pneumococci.  One injection of ceftriaxone is insufficient 
against nonsusceptible pneumococci, with a bacteriologic 
failure rate of approximately 40%.19 
The American Academy of Pediatrics guidelines18 
differentiate between the first episode of AOM or no AOM 
within the last 3 months, and recalcitrant, recurrent, or 
nonresponsive AOM.  A limited choice of antibiotics is 
recommended.  For first episode cases (simple, 
uncomplicated AOM), the choice is between regular and 
high doses of amoxicillin and amoxicillin/clavulanate.  
Cefuroxime or one injection of ceftriaxone (for those 
unable to take oral therapy) are additional alternatives.  If 
the patient has received antibiotics for AOM during the 
last month or if he attends a child care center, 
recommendations are for a high dose of amoxicillin/ 
clavulanate. A high dose of amoxicillin or amoxicillin/ 
clavulanate or 3 doses of ceftriaxone are necessary for 
recurrent or nonresponsive AOM.  It is prudent to 
consider culturing otorrhea, from PE tubes or 
perforated tympanic membranes, given the changing 
epidemiology of SN, Hi, and CA-MRSA.  At Texas
Children’s Hospital, serotype 19A has become the most 
common pneumococcal serotype isolated from chronic or 
recurrent pneumococcal sinusitis and mastoiditis patients 
with 68% multidrug resistance noted in the latter, making 
physicians aware of a more aggressive and complicated 
infection to treat.20,21,22 
The CDC’s Active Bacterial Core Surveillance Network 
(“ABC sites”) documented rates of pneumococcal 
meningitis have decreased among children/adults since 
PCV7 was introduced.  Although the overall effect of the 
vaccine remains substantial, a recent increase in 
meningitis caused by non-vaccine serotypes, including 
strains non-susceptible to select antibiotics is
concerning23. Researchers studied pneumococcal 
meningitis rates 1998-2005 and compared years with 
baseline values from 1998-1999 (PCV7 introduced in 
2000).  Overall rates of PCV7-serotype meningitis 
decreased 73.3%, and PCV7 related serotype disease 
decreased 32.1%.  However, rates of non-PCV7-serotype
disease increased from 0.32 cases per 100,000 people to 
0.51 cases per 100,000 people with significant increase in 
non-PCV7 serotypes 19A, 
22F, 35B (2004-2005 
The increased pneumococcal meningitis 
parapneumonic empyema incidence - 0.29 case per 
100,000 people).  Overallprevalence includes 61% meningitis incidence rates 
with negative bacterial in patients younger than 2 
cultures with suspicion years decreased 64% and 
adults 64 years and older, that non-vaccine 
rate decreased 54%. 
pneumococcal serotypes 
Vanderbilt University and are responsible, along CDC researchers utilizing 
with prior antibiotic a nationwide data-base 
therapy.25 sampling 1997-2006 
revealed pneumococcal 
conjugated vaccine (PCV7)
remains effective against childhood pneumonia.  Both 
2005 and 2006 rates were 27% and 35% lower than 
baseline rate for all-cause pneumonia hospitalizations in 
children younger than two years including for 2006 36,300 
fewer pneumonia hospitalizations.24  Up to a five-fold 
increase in parapneumonic empyema has been found in 
the post-pneumococcal conjugate vaccine era.   
Similar studies from eight children’s hospitals26 and Utah27 
identified the most prevalent pneumococcal serotypes 
isolated were 1, 3, 6, 14, and 19A, most all non-vaccine 
serotypes.  Empyemas that are culture-negative can 
be managed in a similar fashion to those that are 
known to be caused by S. pneumoniae.
(Continued on page 6)
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(Continued from page 5)
In 2008, the Clinical and Laboratory Standards Institute 
(CLSI) and the FDA revised susceptibility breakpoints for 
penicillin and Streptococcus pneumoniae for non-
meningeal infections in patients receiving intravenous
penicillin (susceptible, intermediate, resistant) with the 
respective new breakpoints = 2, 4, and 8 mcg/ml.  For 
meningitis, the figures change to 0.06 for susceptible and 
= 0.12 mcg/ml for resistant.  The in vitro penicillin 
susceptibility of pneumococcal isolates = 0.06, 0.12, and 
= 2 mcg/ml respectively still pertain for patients being 
treated with oral penicillins as outpatients.  The scientific 
basis for the revisions to the breakpoints was supported 
by microbiologic, pharmacokinetic and/or 
pharmacodynamic, and clinical data.  Clinicians, once 
again should feel comfortable prescribing penicillin 
for pneumococcal pneumonia and other 
pneumococcal infections outside the central nervous 
system.28  Beta lactams should be used cautiously in
lung infections caused by pneumococci with minimum 
inhibiting concentrations (MICs) of 4 mcg/ml or more
because therapeutic failures have been seen.17 
“Use of narrow spectrum agents, such as penicillin, is 
encouraged to prevent the spread of antimicrobial-
resistant S. pneumoniae and also the spread of 
methicillin-resistant Staphylococcus aureus (MRSA) 
and Clostridium difficile, which can result from use of 
broader-spectrum antimicrobials.  The changes in 
penicillin breakpoints for S. pneumoniae have the 
potential to allow clinicians to increase use of 
penicillin to treat penicillin-susceptible non-meningitis 
pneumococcal infections, instead of using broader-
spectrum antimicrobials.”(CDC)29 
The 13-valent pneumococcal conjugate vaccine (PCV) 
had been granted fast-track status for the pediatric 
indication based on “an unmet medical need,” with goal 
replacement of PCV7, with PCV13 using a technology
that worked successfully with Prevnar.  The 13-valent 
version contains the same 7 serotypes in Prevnar (4, 6B, 
9V, 14, 18C, 19F, 23F) along with six new pneumococcal 
strains (1, 3, 5, 6A, 7F, 19A).  In 2006, the proportion of 
invasive pneumococcal cases caused by the 7 strains in 
Prevnar was 2% in children less than 2 years of age and 
4% in those aged 2-4 years.  The proportion of invasive
pneumococcal disease (IPD) cases caused by the 13
serotypes in the new version was 64% and 73% 
respectively, with half of the cases due to 19A.  Data has 
shown a single dose of PCV13 will induce an immune 
response to the six new serotypes in more than 90% of 
children aged 12 months and older.  Thus, potentially
after completion of the primary three-dose series with 
PCV7, after age 12 months a child could receive simply
the PCV13 as a booster.  Final recommendations were 
published March 2010.74,75 
Clostridium difficile Epidemiology/Clinical Update 
The incidence of Clostridium difficile – associated disease 
(CDAD) is increasing in both inpatients and outpatients
worldwide with an accompanying increased severity.30 
U.S. hospital 
discharge data Community-associated reveals in less than 
CDAD is now occurring in per-a decade a 
doubling of sons who lack traditional risk 
CDAD.31  Cases of factors, which included antibi-
CDAD at children’s 
otic use, advanced age, and hospitals increased 
significantly severe underlying disease. 
between 2001 and 
2006 with an 
annual rate increase of 53% including an 85% increase in 
cases among children ages 1-5 years.32  Greater 
frequency and severity of CDAD have been linked to a 
previously uncommon and more virulent strain of C. 
difficile, identified as the BI/NAP1/027 strain.  The 
incidence of CDAD is increasing in both inpatients and 
outpatients with more complications seen in the outbreaks 
caused by this hypervirulent strain, which produces more 
than 15 times toxins A and B than previously identified
strains33. 
The hypervirulent strain of CDAD accounted for 10-38% 
of isolates of hospitalized children34 with a complication 
rate of 29% versus 6% with other strains.  Many 
authorities suspect additional contributing factors may 
include increased fluoroquinolone use in the community 
(most commonly used antimicrobials in N. America with 
BI/NAP1/027 strain highly resistant to quinolones) and an 
increase in proton pump inhibitor exposure.30 CDAD is 
an unintended consequence of antimicrobial use, 
now in the community (including otherwise healthy
persons) and hospital settings.  Vital to its prevention 
is judicious use of antibiotics and antimicrobial 
stewardship.  
Community-Associated Methicillin-Resistant 
Staphylococcus aureus Epidemiology/Clinical Update 
Staphylococcal infections encompass a spectrum from
relatively mild localized infections to rapidly fatal invasive 
infections.  In the 1990s, new strains of MRSA emerged 
as a cause of infection among otherwise healthy people in 
(Continued on page 7)
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Bad Bugs, Including No ESKAPE 
(Continued from page 6)
the community, 
adding to the 
Competitive exclusion of HA-burden of 
community- MRSA by CA-MRSA (mainly USA 
associated S. 300 clone) will occur, withaureus
infections. increased severity of CA-MRSA 
Community- infections resulting in longer
associated 
hospitalizations and a larger in-methicillin-
resistant S. hospital reservoir of CA-MRSA.36 
aureus (CA-
MRSA) isolates 
have a distinct pathogenesis, epidemiology, and clinical 
manifestations that differ from those of healthcare-
associated MRSA (HA-MRSA) isolates.  The USA 300 
clone, and to a lesser extent the USA 400 variant, have 
emerged as the predominant causes of CA-MRSA 
disease35. Epidemiologic models strongly suggest that the 
community-acquired strain will soon become the major 
MRSA strain in the hospital setting, surpassing and 
replacing the healthcare-associated MRSA (HA-MRSA) 
strain.
Also noted, hand hygiene has the greatest return of 
benefits, and if compliance is optimized, other 
strategies may have minimal added benefit.36 
It is also becoming clear 
Today, MRSA accounts that antimicrobial 
resistance is an increasing for 50-70% of all S. 
problem outside ofaureus isolates with a 
hospitals.  The CDC Active$4.2 billion annual Bacterial Core Surveillance 
financial impact in the Network (“ABC sites”) noted
United States.37 the estimated rate of invasive 
(bloodstream or other sterile 
site) MRSA infections in 2005 was 31.8 per 100,000 
persons.  This estimated rate of invasive MRSA infections
was greater than the combined rate in 2005 of invasive 
pneumococcal disease (14.1 per 100,000), invasive group 
A streptococcal infection (3.6 per 100,000), invasive 
meningococcal disease (0.35 per 100,000), and invasive 
Haemophilus influenzae infection (1.4 per 100,000).38 
Among 5287 surveyed patients hospitalized with MRSA 
infection during 2005, 988 deaths occurred.  
Based on these data, it was estimated that there were 
18,650 patients who died of invasive MRSA infection in
the U.S. in 2005 – exceeding the total number of deaths 
attributable to HIV/AIDS in the U.S. during that year.39 
A study from the CDC found that 6% of CA-MRSA 
infections were invasive40 and a pediatric study noted 9% 
of children hospitalized in 2003 for CA-MRSA infection had 
invasive disease.41 
CA-MRSA, a new pathogen for children and adults, may 
represent up to 50-80% of all S. aureus community isolates 
in various regions of the U.S.  CA-MRSA is resistant to
methicillin and to all other beta-lactam antibiotics that are 
FDA approved to date.  In contrast to HA-MRSA, CA-
MRSA usually does not have multiple antibiotic resistance 
genes.  However, there are an undetermined number of 
pathogenicity factors that appear to make CA-MRSA more 
aggressive than methicillin-susceptible S. aureus (MSSA).  
Compared with MSSA, CA-MRSA appears to cause 
greater tissue necrosis, an increased host inflammatory 
response, an increased rate of complications, and an 
increased rate of recurrent infections.  Response to therapy 
with non-beta-lactam antibiotics appears to be delayed.  It 
is unknown whether higher dosages and longer courses of 
alternative agents needed for clinical cure are due to a 
hardier, better-adapted pathogen, or whether alternative 
agents are not as effective as beta-lactam agents were 
against MSSA. No data are currently available to 
compare one antibiotic against another for CA-MRSA, 
let alone one combination against another.
Transmission of CA-MRSA strains and infections to close 
contacts has frequently been reported.  A prospective study 
of CA-MRSA infected patients showed that reports of new 
skin infection among household members in the 30 days 
after the initial infection was 13% for CA-MRSA patients but 
4% for those who had CA-MSSA infections.42 In military
recruits who were colonized on entry into boot camp, 
any antibiotic use during the previous 6 months was a 
risk factor for nasal colonization with CA-MRSA.  Nasal 
colonization resolved within weeks; however, subsequent 
infections developed in 38% of those with nasal 
colonization, compared with 3% of those without 
colonization.43  The 2008 ICAAC/IDSA meeting had a 
recent three year study from the Chicago hospital system 
revealing patients with S. aureus (40% had MRSA) who 
had been treated with antibiotics within the past 3 months 
may be at increased risk for MRSA serious infections. 
There are limited published data on MRSA in child care 
centers.  Recent data from the 2008 Interscience 
Conference on Antimicrobial Agents and Chemotherapy 
(ICAAC) and the Infectious Diseases Society of America 
(IDSA) noted that 7% of children were colonized, employee 
colonization was 3%, and among family members of 
children or staff found to carry MRSA, 35% were also
colonized.  Findings indicated children treated with a 
(Continued on page 8)
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macrolide antibiotic in the past were at increased risk for 
MRSA colonization.  Genetic analysis revealed many 
isolated strains were related implying that transmission of 
MRSA may be occurring in the child care setting.  S. 
aureus cultured from nares did not match wound isolates in 
many children with skin infections with a 33% 
discordance.44  The MRSA colonization rate in elementary 
school children was 0.5-0.9% over three years with an
increase in CA-MRSA strains.45 
To date, frank resistance to vancomycin is rare; however, 
true intermediate resistance (MIC 4-8 mcg/ml), vancomycin 
intermediate S. aureus (VISA), and vancomycin hetero-
resistance (hVISA) are encountered.  Serious infections 
caused by hVISA/VISA strains are associated with poor 
clinical outcomes,46 with a recent international cohort 
of patients revealing the hVISA phenotype occurring in 
more than one-quarter of MRSA ineffective 
endocarditis isolates and was associated with a higher 
frequency of complications, i.e., persistent bacteremia 
and heart failure.47 
Hetero-resistance refers to the presence, within a large 
population of fully antimicrobial-susceptible 
microorganisms, of subpopulations with lesser 
susceptibility.  Current focus revolves around hetero-
resistance to vancomycin.  Hetero-resistant subpopulations 
of vancomycin-susceptible S. aureus (hVISA) were first 
described in 1997 shortly after the initial description of 
vancomycin intermediately susceptible strains (VISA).  
hVISA have 
It is impossible to ignore reports of minimum inhibitory 
rising vancomycin MICs and the concentrations
(MICs) in the effect that higher vancomycin MICs 
intermediatelywithin the susceptible range seem 
susceptible range to have on treatment outcomes. and likely represent 
There is also some evidence that a step on the path to 
the development of a exposure to subtherapeutic
fully VISAconcentrations may tend to select
population.  Recent for reduced susceptibility to U.S. reports note 
vancomycin.  Also under selective hVISA having been
pressure from vancomycin, a series identified among 
of sequential mutations are selected clinical isolates of 
for as an organism transitions from MRSA with an 8-9% 
full susceptibility to hVISA to VISA. frequency and a 
recent international 
study with  infective 
endocarditis isolates a prevalence of 13.9% (N. America), 
35% (Europe), and 77.8% (Oceania).47,48,49 Vancomycin 
hetero-resistance is present in both hospital and 
community strains of S. aureus. The proportion of MRSA 
isolates demonstrating hetero-resistance increases with 
increasing vancomycin MICs, but hetero-resistance is
observed in strains with MICs as low as 1.0 mcg/ml.  The 
phenomenon is inducible and may be either stable or
unstable.  As compared with MRSA bacteremia, hVISA 
bacteremia may be associated with prolonged 
bacteremia duration, greater rates of complications, 
and emergence of rifampin resistance.50,51 
Challenges, but vancomycin remains a drug of choice, the 
standard treatment for serious MRSA infections and 
serious MSSA infections in patients with B-lactam allergies.
To date, most clinical trials have not demonstrated 
superiority of new agents.52  However, vancomycin 
resistance is a growing concern as data from several 
reports suggests a correlation between increased MICs, 
and treatment failure.  Generally, current glycopeptides
(e.g. vancomycin) are less efficacious than B-lactams 
against MSSA. However, vancomycin is still a gold 
standard against severe MRSA infections, until proof is 
found of newer anti-MRSA drugs.53 
Increases in serious invasive CA-MRSA infections continue 
with many patients with endemic disease, particularly
children, having no discernible risks.  Several trends of CA-
MRSA infections have been associated with some clinical 
manifestations of S. aureus infections, such as deep 
venous thromboses (DVT), pyomyositis, and neonatal 
disease that had not been seen commonly while there are 
relatively few existing data on effective therapy with these 
infections.  There is a paucity of literature examining the 
epidemiology of CA-MRSA infections, especially skin 
infections.  Skin and soft tissue infections (SSTI) account 
for approximately 85-95% of CA-MRSA infections54 in 
children and adults with SSTI caused by CA-MRSA more 
severe than those caused by CA-MSSA isolates.55 
Recurrent skin infections are encountered in about 10% of 
patients with SSTI.56 Basics apply, with incision and 
drainage and obtaining cultures used to assess for 
MRSA with uncomplicated SSTI.
Medical management of SSTI with antimicrobials has been 
addressed in previous publications and mailings by the SC 
DHEC Bureau of Disease Control (see “Outpatient 
Management of Skin & Soft Tissue Infections in the Era of 
Community-Associated MRSA,” April 2008 – available from 
http://www.scdhec.gov/health/disease/acute/mrsa.htm). 
Necrotizing pneumonia (especially with influenza), 
empyema, sepsis syndrome, purpura fulminans, 
Waterhouse-Friderichsen syndrome, and necrotizing 
fasciitis have all been associated with CA-MRSA.  
Musculoskeletal infections such as osteomyelitis and 
(Continued on page 9)
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pyomyositis are also increasing in prevalence.  Patients 
with CA-MRSA experience longer duration of fever, 
prolonged hospital stays, and more complicated 
clinical courses when compared with patients with CA-
MSSA55, especially if the isolate contains genes 
encoding for Panton-Valentine leukocidin (PVL) toxin.  
Osteomyelitis accounted for 7.5% of all MRSA infections 
(CA-MRSA or HA-MRSA) among all age groups by CDC 
reported surveillance of invasive MRSA infections for the 
ABC sites.38  Musculoskeletal infections are the most 
common invasive infections caused by CA-MRSA in 
children.  Osteomyelitis with CA-MRSA had greater
inflammation with increased white blood cell count, ESR, 
CRP, greater frequency of positive blood cultures, greater 
admission to intensive care units, greater frequency 
subperiosteal intraosseous abscesses, prolonged 
bacteremia, increased frequency surrounding myositis, and 
a tendency more often for multiple sites of infection, 15%.57 
Optimal antibiotic therapy duration has yet to be 
established but can range from 6-10 weeks.  CA-MRSA 
complications include chronic osteomyelitis or an 
associated deep venous thrombosis, adjacent to the 
infected bone.  Venous thrombophlebitis leading to septic 
pulmonary emboli and other sites of dissemination occurs 
more commonly with CA-MRSA isolates, especially the 
USA 300 clone.  There are increasing reports of 
osteomyelitis in adults involving USA 300 CA-MRSA strains 
with complications of septic emboli or pathologic fractures 
as seen in children.58 
Multiple sites of myositis/pyomyositis and/or
osteomyelitis can develop in a patient with 
disseminated S. aureus infection necessitating 
careful exams of patient daily to detect areas of 
infection and/or abscesses that may not have been 
appreciated even the previous day with a necessity 
often of repetitive MRI studies. 
CA-MRSA pyomyositis in adult reports includes postpartum 
women.59  MRI is the most sensitive modality for early
diagnosis of musculoskeletal infections.  It can demonstrate 
the bone changes consistent with osteomyelitis and identify 
bone and subperiosteal abscesses, myositis/pyomyositis 
(an elevated creatine kinase, CK, may be seen in some 
cases), and most venous thromboses (ultrasound utilizing 
Doppler flow diagnostic modality of choice).  Bone scans 
may be useful when the site(s) of infection is not clearly 
localized.60 
Complicated pneumonias with empyema with CA-MRSA 
isolates have become common with some children’s 
hospitals with CA-MRSA the most common pathogen with 
pleural empyema.  Lung 
involvement may be a Lung involvement is an
severe pulmonary important feature of the 
syndrome with a rapidly sepsis syndrome.  Pulmonary progressing necrotizing 
manifestations are diverse pneumonia usually 
preceded by flu-like including pulmonary emboli, 
symptoms (classically necrotizing pneumonia, lung 
hemoptysis, leukopenia, abscess, and empyema 
lung necrosis among the most significant.62 radiologically) with a 
In patients who present withmortality rate 76%.61 
Necrotizing pneumonia osteomyelitis and shortness 
patients may not have of breath, respiratory 
positive S. aureus blood distress, or chest pain, 
cultures but sputum pulmonary emboli from ancultures or
endovascular source (DVT) bronchoalveolar lavage 

will usually be S. aureus should be sought.  

positive. 

Sepsis syndrome, occurring in all age groups, has 

increased with CA-MRSA and is seen most often in 

children less than 4 years of age and in adolescents.  Most 

patients had musculoskeletal infections (2-10 sites in some 

series), bacteremia, and pulmonary involvement with 

common complications vascular thrombosis, multiple areas 

pyomyositis, subcutaneous nodules, and purpura 

fulminans.  Clinical features include leukopenia (initial white 

blood cell count may be normal), neutropenia, profound
 
tachycardia, lactic acidosis, and thrombocytopenia and/or 

disseminated
 
intravascular Most patients with S. aureus 

coagulation.  
 sepsis syndrome have more 
Leukocytosis or 
than one positive bloodleukopenia may be 
seen in patients, with culture. Prolonged bacteremia 
leukopenia indicating is common and suggests an 
a more ominous 
un-drained focus of infection prognosis.  With 
osteomyelitis or an endovascular source 
involvement, higher (i.e., DVT or endocarditis) 
CRP and ESR 
rather than an antibioticadmission levels
have been failure. Patients with severe 
associated with a sepsis syndrome should havehigher likelihood of 

complications.63 echocardiography assessment. 

(Continued on page 10)
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CA-MRSA infections are being recognized more commonly 
in the otherwise healthy neonate less than 30 days of age, 
with the most common manifestation pustulosis.64  Most
cases of localized pustulosis appear to be adequately 
treated with topical treatment, mupirocin.  Blood culture is 
recommended for diffuse pustulosis but treatment could be 
an oral antibiotic such as clindamycin.65  Abscesses, 
cellulitis, and other invasive infections, although less 
common, can be associated with bacteremia and more 
severe illness. Any infant with symptoms or with fever 
related to potential S. aureus infection, should undergo 
a complete evaluation including blood, urine, and CSF 
analysis and culture,55,65 and hospitalization 
assessment. 
Rapid institution of appropriate antimicrobial therapy 
is critical in the treatment of severe S. aureus
infections, as delay in therapy has been associated 
with increased mortality.68  The American Academy 
of Pediatrics (AAP) Red Book recommends a 
combination of vancomycin, nafcillin (more rapidly 
bactericidal than vancomycin for MSSA isolates
including adult clinical data for treatment of 
bacteremic pneumonia secondary to MSSA), and 
gentamicin for the initial empiric treatment of severe 
and critically ill/life-threatening S. aureus infections. 
Poorer outcomes are associated with MRSA versus MSSA 
infections with a significant health care burden in terms of 
morbidity, mortality, and economic cost associated with the 
disease. A meta-analysis of 31 cohort studies (1980-
2000) determined that a significant increase in 
mortality was specifically associated with MRSA 
bacteremia.66  Also, patients with MRSA have higher 
inpatient costs, and longer hospital stays compared to 
patients with MSSA.67 
However, no data support any one combination of therapy 
as being more efficacious than another.  Pediatric patient 
recommendations are based on adult bacteremia and 
endocarditis data and on clinical experience accumulated 
with treatment of severe infections in pediatric hospitals.  If
bacteremia/septicemia, endocarditis/endovascular, or 
CNS infection may be involved, vancomycin is the 
mainstay of therapy.  Clindamycin remains an important 
option for treating serious non-endovascular infections in 
children due to susceptible isolates.   
New recommendations for targeting and adjustment 
of vancomycin therapy resulted from updated and
existing evidence regarding vancomycin dosing and 
monitoring of serum concentrations, patient 
outcomes, and vancomycin’s pharmacokinetic, 
pharmacodynamic, and safety record.  The 
relationship between serum concentrations and 
treatment success or failure in serious S. aureus 
infections has recently been established. 
New practice guidelines for therapeutic monitoring of 
vancomycin treatment for S. aureus infections in adult
patients were reviewed by an expert panel of the Infectious 
Diseases Society of America, the American Society of 
Health-System Pharmacists, and the Society of Infectious 
Diseases Pharmacists.69 
Failure rates exceed 60% for S. aureus with a vancomycin 
MIC value of 4 mcg/ml and recently studies established a 
relationship between vancomycin treatment failures and 
infections in patients with MRSA with MIC of 2mcg/ml.  
Vancomycin’s (concentration independent activity against 
S. aureus) primary predictive pharmacodynamic parameter 
for efficacy is the area under the concentration curve (AUC) 
divided by the MIC with data supporting an AUC/MIC value 
of 400 the pharmokinetic – pharmacodynamic target.  To 
achieve this target, larger vancomycin doses and high 
trough serum concentrations are required.  The 
following is a summary of therapeutic vancomycin 
dose adjustment (better prognosis with initial dosage
therapeutic levels) and drug monitoring. 
Initial vancomycin dosages should be calculated based on 
actual body weight (including for obese patients) with
subsequent dosages based on actual serum 
concentrations to achieve targeted therapeutic 
concentrations.  Continuous infusion regimens are unlikely 
to substantially improve patient outcome.  Trough serum 
concentrations (most accurate and practical for monitoring 
vancomycin effectiveness) should be obtained just before 
the fourth dose at steady state conditions.  It is 
recommended that trough serum vancomycin 
concentrations always be maintained at > 10 mcg/ml to 
avoid the development of resistance (evidence suggests 
S. aureus exposure to < 10 mcg/ml troughs can 
produce strains with VISA-like characteristics). 
This trough level range should achieve a targeted AUC/ 
MIC > 400 for most patients if the MIC is < 1 mcg/ml.  The 
targeted AUC/MIC is not achievable with conventional 
(Continued on page 11)
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most patients with normal 
dosing methods if the 
Trough serum vancomycin vancomycin MIC is = 2 
concentrations of 15-20 mcg/ml for a patient with 
normal renal function mcg/ml are recommended 
(alternative therapies 
with the potential to should be considered).  
improve penetration, to Vancomycin dosages of 
increase the probability of 15-20 mg/kg (actual body 
weight) given every 8-12 optimal target serum 
hours are required for concentrations, and to 
improve clinical outcomes renal function to achieve 
of complicated infections the suggested trough 
such as S. aureus serum concentrations
when the MIC is < 1 mcg/ bacteremia, endocarditis, 
ml. To achieve rapid osteomyelitis, meningitis, attainment of target
and hospital-acquired concentration for seriously 
pneumonia. ill patients, a loading dose 
of 25-30 mg/kg can be 
considered.  When
individual doses exceed 1 gram (1.5 and 2g), the infusion 
period should be extended to 1.5-2 hours.   
There are limited data suggesting a direct causal 
relationship between toxicity and specific serum 
vancomycin concentrations.  The safety of higher trough 
vancomycin concentrations over a prolonged period 
continues to be studied.  Monitoring of trough serum
concentrations to reduce nephrotoxicity is best suited for 
patients receiving aggressive dose targeting (for sustained 
trough serum concentrations of 15-20 mcg/ml) or who are 
at risk of toxicity (patients with concurrent treatment with
nephrotoxins).  Monitoring is also recommended for 
patients with unstable renal function and for patients with 
prolonged courses of therapy (>3-5 days).  Exact frequency 
of monitoring is often a matter of clinical judgment with
recommendations frequent trough concentrations in 
hemodynamically unstable patients (sometimes daily) and 
when a 15-20 mcg/ml vancomycin concentration is desired, 
once weekly, measurements of trough concentration for 
hemodynamically stable patients.  Frequent monitoring for 
short course therapy (less than 5 days) or for lower 
intensity dosing (trough concentration < 15 mcg/ml) is not 
recommended.  
It is unknown whether recommended vancomycin dosing 
regimens for children achieve an adequate AUC/MIC value 
and unfortunately, the response to therapy using standard 
vancomycin dosing (40 mg/kg/day) in treating CA-MRSA 
strains has not been as predictably good as in the past.  
Retrospective and modeling data indicate standard dosing 
does not achieve the pharmacodynamic target over 24 
hours of AUC/MIC = 400 for optimally treating MRSA 
isolates with a MIC of 1.0 mcg/ml or greater.70 
Recommendations of a more effective increased starting 
dosage, to maintain a range of trough concentration 15-20 
mcg/ml, can be made for children with normal renal 
function and suspected or proven invasive MRSA infections
(60 mg/kg/d – 15 mg/kg intravenously every six hours).  
With a higher treatment dose, one needs to follow renal 
function, but children appear to tolerate this higher dosage
much better than do adults.  
SUMMARY 
An analysis published last year noted a return to pre-
antibiotic conditions may occur as a result of antibiotic 
abuse and declining development of new medicines.  
Currently there are no new classes of antibiotics entering 
late-stage clinical development.  Are we entering a post-
antibiotic era?  Resistance trends may be moving at a 
faster pace, in both hospital and community settings, than 
previously believed.71 
People need to know that antibiotic overuse may 
put them at increased risk for a more virulent C. 
difficile disease and more invasive resistant 
infections in the future including S. pneumoniae, 
MRSA, vancomycin-resistant Enterococcus, and 
other ESKAPE organisms in a nosocomial setting.   
With additional media coverage now addressing increased 
carriage of more resistant and virulent pneumococcus and 
MRSA, the public demand for antibiotics may decrease 
with resistance education and viable alternatives to 
antibiotics. Additional media exposure includes coverage 
addressing the internet purchase of antibiotics, the 
significant impact of adverse effects of antibiotics, and the 
potential relationship to increased childhood asthma and 
the use of antibiotics in the first year of life, with the risk 
increasing with the number of courses of antibiotics 
prescribed.72 
Efforts to sustain the lifespan of current antibiotics are 
vital and must originate in primary care practices.  One 
cannot be expected to change decades of patient behavior 
overnight and patients cannot be expected to limit their 
antibiotic use to promote the greater common good of
resistance prevention.  However, after decades of 
antibiotic use and abuse, contemporary data now
permit health care providers to highlight real risks for 
(Continued on page 12)
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individual patients expecting antimicrobials for viral syndromes. This may permit an improvement in judicious use 
of antibiotics for upper respiratory infections with earlier addressed guidelines on the SC DHEC website (in SC, patients 
receiving antibiotics for the common cold has decreased in the past few years from 42 to 29%).  We hope that this Epi 
Notes update will help clinicians continue to take the necessary steps for their patients to reduce the impact of 
antimicrobial resistance in a changing inpatient and outpatient clinical environment. 
Read more about CAreful Use of antibiotics (CAUse): http://www.scdhec.gov/health/disease/sccause/index.htm. 
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Year-to-Date Summary of Reportable Conditions ‡ 

January 1, 2010 to March 15, 2010
 
Reportable Condition Confirmed Probable Total
Animal Bites – PEP recommended 28 * 28 
Arboviral Neuroinvasive Disease (includes West Nile Virus) 0 0 0 
Brucellosis 0 0 0 
Campylobacter enteriditis 39 0 39 
Cryptosporidiosis 7 0 7 
Cyclosporiasis 0 0 0 
Ehrlichiosis 0 0 0 
Enterohemorrhagic E. Coli (includes O157:H7) 1 0 1 
Giardiasis 17 0 17 
Haemophilus influenza 26 0 26 
Hemolytic uremic syndrome 0 0 0 
Hepatitis A, acute 9 0 9 
Hepatitis B, acute 10 1 11 
Hepatitis B, chronic 12 87 99 
Hepatitis C, acute 0 0 0 
Hepatitis C, chronic or past 666 3 669 
Influenza, positive virus culture isolates (not Novel) 19 0 19 
Influenza, Novel Influenza A Virus Infections (H1N1) 147 0 147 
Legionellosis 1 0 1 
Listeriosis 2 0 2 
Lyme disease 3 0 4 
Malaria 1 0 1 
Measles (rubeola) 0 0 0 
Meningitis, aseptic 23 0 23 
Meningococcal disease 4 0 4 
Mumps 1 0 1 
Pertussis 36 3 39 
Psittacosis 0 0 0 
Rocky Mountain Spotted Fever 0 0 0 
Rubella (includes congenital) 0 0 0 
Salmonellosis 81 0 81 
Shigellosis 17 0 17 
Staphylococcus aureus, vancomycin-resistant (VRSA/VISA) 0 0 0 
Streptococcus group A, invasive disease 25 0 25 
Streptococcus group B, age < 90 days 18 0 18 
Streptococcus pneumoniae, invasive 164 0 164 
Varicella (only outbreak associated or hospitalized cases are reportable) 44 0 44 
Vibrio infections (non-cholera) 1 0 1 
Yersiniosis 3 0 3 
‡   To save space, several conditions with zero reported cases in 2010 were omitted from this list. 
* Probable cases status is not allowed for this condition.
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